Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News Japanese group AGC offers €240m bid for Italian biotech company Molmed Japanese conglomerate AGC has offered a takeover bid of €240 million to acquire 100% of Italian biotech company… bypharmanewsdailyMarch 18, 2020
